The Role of Benzalkonium Chloride in the Occurrence of Punctate Keratitis: A Meta-Analysis of Randomized,Controlled Clinical Trials

Abstract

Spanish

French

Background:

Benzalkonium chloride (BAK), the most commonly used preservative in topical ophthalmic solutions, has undergone considerable criticism in recent years, principally based on in vitro and in vivo studies. Relevance to the clinical setting has not been confirmed.

Objective:

To determine whether administration of twice the amount of BAK was associated with an increased incidence of punctate keratitis in long-term, double-masked trials comparing latanoprost ophthalmic solution and vehicle with timolol ophthalmic solution in patients with glaucoma or ocular hypertension.

Methods:

A meta-analysis of the double-masked phases of 7 prospective, controlled clinical trials compared the incidence of punctate keratitis among patients assigned to treatment with latanoprost or timolol. In all studies, the amount of BAK administered daily in the latanoprost arms was approximately twice the amount used in the timolol arms. All reports of punctate keratitis either as a finding or an adverse event were included. A fixed-effect model was used because the heterogeneity was small and not statistically significant. Sensitivity analyses were conducted. Funnel plots were provided to address potential publication bias.

Results:

Of the 1694 patients enrolled in the double-masked portion of the trials (latanoprost, n = 892; timolol, n = 802), the overall incidence of punctate keratitis was 6.3% (106/1694). The incidence in latanoprost-treated patients was 6.5% and in timolol-treated patients was 6.0%. The risk difference for punctate keratitis of latanoprost versus timolol was 0.005 (95% CI –0.011 to 0.020; p = 0.574), and the risk ratio of latanoprost versus timolol was 1.084 (95% CI 0.739 to 1.589; p = 0.680).

Conclusions:

These results indicate that BAK does not produce significant corneal toxicity in the vast majority of patients with glaucoma or ocular hypertension at the concentrations used in these studies.

Keywords

benzalkonium chloride latanoprost meta-analysis punctate keratitis timolol

Get full access to this article

View all access options for this article.

References

Rahman

, Tejwani

, Wilson

, Butcher

, Ramaesh

. Microbial contamination of preservative free eye drops in multiple application containers. Br J Ophthalmol 2006; 90:139–41.DOI 10.1136/bjo.2005.078386

Yee

. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol 2007; 18:134–9. DOI 10.1097/ICU.0b013e328089flc8

Baudouin

, Riancho

, Warnet

, Brignole

. In vitro studies of anti-glaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 2007; 48:4123–8. DOI 10.1167/iovs07-0266

Baudouin

, Pisella

, Fillacier

. Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Ophthalmology 1999; 106:556–63. DOI 10.1016/S0161-6420(99)90116-1

Noecker

, Herrygers

, Anwaruddin

. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004; 23:490–6. DOI 10.1097/01.ico.0000116526.57227.82

Whitson

, Cavanagh

, Lakshman

, Petroli

. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther 2006; 23:1–9. DOI 10.1007/BF02850305

Yee

, Norcum

, Zhao

. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther 2006; 23:511–9. DOI 10.1007/BF02850039

Cha

, Lee

, Oum

, Kim

. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Exp Ophthalmol 2004; 32:180–4. DOI 10.1111/j.1442-9071.2004.00782.x

De Saint Jean

, Brignole

, Bringuier

, Bauchet

, Feldmann

, Baudouin

. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999; 40:619–30.

10.

Burstein

. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci 1980; 19:308–13.

11.

Gasset

, Ishii

, Kaufman

, Miller

. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol 1974; 78:98–105.

12.

Hoffman

, Choi

, Clousing

, Ubels

, McCarey

, Edelhauser

. Corneal epithelial testing strategies for safety evaluation of ophthalmic medications. Cutan Ocul Toxicol 2007; 26:311–27. DOI 10.1080/15569520701588780

13.

Khoh-Reiter

, Jessen

. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol 2009; 16:98–103.

14.

Alm

, Stjernschantz

. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995; 102:1743–52.

15.

Camras

. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996; 103:138–47.

16.

Dart

. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease. Eye 2003; 17:886–92. DOI 10.1038/sj.eye.6700576.

17.

Thygesen

, Aaen

, Theodorsen

, Kessing

, Prause

. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand 2000; 78:37–44. DOI 10.1034/j.1600-0420.2000.078001037.x

18.

Watson

. Latanoprost: two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 1998; 105:82–7.

19.

Watson

, Stjernschantz

. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996; 103:126–37.

20.

Mauger

, Craig

, Havener

. Wetting agents and tear substitutes (Chapter 13). In: Mauger

, Craig

, eds. Havener's ocular pharmacology. 6th ed. St. Louis, MO: Mosby Year Book, Inc., 1994; 492–505.

21.

Pisella

. Conjunctival markers as predictable markers for preoperative glaucoma assessment. Br J Ophthalmol 2006; 90:1335–6. DOI 10.1136/bjo.2006.097634

22.

Product information. Iopidine (aproclonidine ophthalmic solution). Ft. Worth, TX: Alcon Laboratories, Inc.; July 1995. http://www.drugs.com/mmx/iopidine.html (accessed 2010 Jul 14).

23.

Fiscella

. Costs of glaucoma medications. Am J Health Syst Pharm 1998; 55:272–5.

24.

Product information. Betoptic S (betaxolol ophthalmic solution). Ft. Worth, TX: Alcon Laboratories, Inc.; May 1999. http://home.intekom.com/pharm/alcon/betopt-s.html (accessed 2010 Jul 14).

25.

Fiscella

, Green

, Patuszynski

, Wilensky

. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003; 136:18–25.

26.

Product information. Lumigan (bimatoprost ophthalmic solution). Irvine, CA: Allergan, Inc.; September 2006. http://www.allergan.com/assets/pdf/Lumigan_pi.pdf (accessed 2010 Jul 14).

27.

Product information. Alphagan (brimonidine ophthalmic solution). Irvine, CA: Allergan, Inc.; October 2005. http://home.intekom.com/pharm/allergan/alphagan.html (accessed 2010 Jul 14).

28.

Product information. Azopt (brinzolamide ophthalmic solution). Ft. Worth, TX: Alcon Laboratories, Inc.; May 2008. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm>id=7875 (accessed 2010 Jul 14).

29.

Product information. Trusopt (dorzolamide ophthalmic solution). Whitehouse Station, NJ: Merck & Co., Inc.; April 2005. http://www.rxdrugnews.com/trusoptsterileophthalmicsolution.merck.php (accessed 2010 Jul 14).

30.

Product information. Cosopt (dorzolamide-timolol ophthalmic solution). Whitehouse Station, NJ: Merck & Co., Inc.; April 2005. http://www.theodora.com/drugs/cosopt_sterile_ophthalmicsolution_merck_html (accessed 2010 Jul 14).

31.

Product information. Xalatan (latanoprost ophthalmic solution). New York, NY: Pfizer Inc.; January 2009. http://www.pfizer.com/files/products/supi_xalatan.pdf (accessed 2010 Jul 14).

32.

Product information. Isopto-carpine (pilocarpine ophthalmic solution). Ft. Worth, Texas: Alcon Laboratories, Inc.; October 1993. http://home.intekom.com/pharm/alcon/i-carpin.html (accessed 2010 Jul 14).

33.

Product information. Timoptic (timolol ophthalmic solution). Whitehouse Station, NJ: Merck & Co.; May 2009. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=12008 (accessed 2010 Jul 14).

34.

Product information. Travatan (travoprost ophthalmic solution). Ft. Worth, TX: Alcon Laboratories, Inc.; May 2006. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6835 (accessed 2010 Jul 14).

35.

Lass

, Eriksson

, Osterling

, Simpson

, Latanoprost Corneal Effects Study Group. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study. Ophthalmology 2001; 108:264–71. DOI 10.1016/S0161-6420(00)00531-5

36.

Pfeiffer

, European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002; 240:893–9.

37.

Higginbotham

, Feldman

, Stiles

, Dubiner

, Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002; 120:915–22.

38.

Mastropasqua

, Carpineto

, Ciancaglini

, Gallenga

. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999; 106:550–5. DOI 10.1016/S0161-6420(99)90115-X

39.

Parrish

, Palmberg

, Sheu

, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135:688–703. DOI 10.1016/S0002-9394(03)00098-9

40.

Netland

, Landry

, Sullivan

. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132:472–84. DOI 10.1016/S0002-9394(01)01177-1

41.

Netland

, Landry

, Sullivan

. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2002; 133:732–3. DOI 10.1016/S0002-9394(02)01397-1

42.

Goldberg

, Li

, Selaru

, Paggiarino

. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2008; 18:408–16.

43.

Jaenen

, Baudouin

, Pouliquen

, Manni

, Figueiredo

, Zeyen

. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341–9.

44.

Lewis

, Katz

, Weiss

. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007; 16:98–103. DOI 10.1097/01.ijg.0000212274.50229.c6

45.

Townley

, Reilly

. Dry eye and irritation comparison of latanoprost 0.005% with the preservative benzalkonium chloride (BAC) versus travoprost 0.004% without BAC (E-abstract 4651). Invest Ophthalmol Vis Sci 2009; 50. http://abstracts.iovs.org//cgi/content/abstract/50/5/4651?sid=d945ad5c-6ef0-4872-bbd9-c4f6adc70fd3 (accessed 2010 Nov 19).

46.

Pauly

, Meloni

, Brignole-Baudouin

, Warnet

, Baudouin

. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci 2009; 50:1644–52. DOI 10.1167/iovs08-2992.